🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

850 results for “Elan” Clear

  1. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Rett Syndrome

    phase 3 small molecule terminated

    2 trials

  2. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizure in Participants With Tuberous Sclerosis Complex

    phase 3 small molecule terminated

    1 trial

  3. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Tuberous Sclerosis Complex

    phase 3 small molecule completed

    2 trials

  4. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizures Associated With EMAS

    phase 3 small molecule terminated

    1 trial

  5. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    3 trials

  6. General anesthesia and opioids

    Elan Pharma International

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  7. Granules for oral suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Niemann-Pick disease type C

    phase 3 small molecule active

    1 trial

  8. IDE196

    IDEAYA Biosciences

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

  9. IDE196 (LXS196), IDE196 (LXS196)

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  10. IM JZP-458

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  11. INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0

    Elan Pharma International

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  12. INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80

    Elan Pharma International

    Immunoglobulin G4-related disease (IgG4-RD)

    phase 3 small molecule active

    1 trial

  13. IO102-IO103

    IO Biotech

    Metastatic Melanoma

    phase 3 small molecule active

    1 trial

  14. Imiquimod

    Elan Pharma International

    Lentigo Maligna

    phase 3 small molecule completed

    1 trial

  15. Influenza vaccine

    Lxo Ireland Designated Activity Company

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  16. Ipilimumab

    Bristol-Myers Squibb

    Melanoma

    phase 3 small molecule completed

    1 trial

  17. JPB898 (Induction and Maintenance)

    Sandoz Pty Ltd

    Melanoma

    phase 3 small molecule terminated

    1 trial

  18. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    3 trials

  19. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  20. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  21. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy With Cataplexy

    phase 3 small molecule completed

    1 trial

  22. JZP598, GEMCITABINE , TRASTUZUMAB , CAPECITABINE , VINORELBINE , ERIBULIN

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources